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Background.+is study explored how patients withmetastatic gastrointestinal stromal tumour (GIST) experience the psychosocial
challenges associated with their disease and its treatment, as well as how that experience influenced their practical, relational,
vocational, and existential life. Methods. +is qualitative study has an explorative design and applied a phenomenological and
hermeneutical approach. We conducted in-depth, semistructured interviews with 20 patients with metastatic GIST in long-term
clinical remission.+e gathered data were interpreted using a thematic analysis. Results. Living withmetastatic GIST, as well as the
side effects of the required medication, led to changes that limited the participants’ daily life. +ey expressed how tiredness,
impaired memory, and physical challenges were among the detrimental impacts of the disease on their family life, vocational life,
social life, and leisure time. Adjustments were necessary to ensure they had sufficient energy to cope with the practical and
relational aspects of everyday life. Feelings of uncertainty stemming from drug resistance, disease progression, and the possibility
of early death were also experienced as challenging. Half the participants stated that it was difficult to keep negative mental health
issues at bay, and all of them considered the time spent waiting for their scheduled follow-up scan to be burdensome. Conclusions.
It is important to focus increased attention on how the daily practical and psychosocial life of patients with chronic cancer,
including metastatic GIST, is affected by their disease. Doing so might provide health-care workers with clues regarding how best
to guide and support such patients throughout their emotional journey and, therefore, to improve their quality of life. As new
medical treatments can also prolong survival and induce long-term clinical remission in relation to several other forms of
metastatic cancer, the findings concerning GIST reported in this study might have widespread implications.
1. Introduction
Gastrointestinal stromal tumour (GIST) is an uncommon
form of cancer that arises in the gastrointestinal tract. It has
an annual incidence of 10–15 cases per million people
worldwide [1], although it is still the most common subtype
of sarcoma [2]. GISTs are most frequently found in the
stomach (40–70%), followed by the small intestine
(20–40%), and 5–15% in the colon or the rectum [3]. Most
GISTs are cured by surgery, but 15–20% have already given
rise to overt metastases at primary diagnosis, and approx-
imately 40% of GISTs that are local at the time of the first
detection will eventually give rise to distant metastases [3].
Metastases are commonly found in the peritoneum or the
liver [3]. Patients with metastatic GISTare typically regarded
as having a chronic cancer. +ey are considered to be in-
curable and, thus, to be dependent on life-prolonging cancer
treatment. Unlike many other forms of cancer, GIST does
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not respond to conventional chemotherapy. In 2001, ima-
tinib was shown to be exceedingly effective in terms of the
treatment of metastatic GIST [4, 5]. +is, along with the
introduction of TKI therapy [6], has resulted in a median
overall survival of approximately seven years [7], whereas
the median overall survival was less than one year during the
pre-imatinib era [8]. Despite this, most GIST patients will
eventually experience drug resistance to TKI therapy [5, 9].
+e treatment of metastatic GIST is a prime example of
how a clinically significant improvement in cancer treatment
can affect the daily practical and psychosocial life of patients
in long-term clinical remission. To date, studies that have
applied a psychosocial perspective on the challenges faced by
patients living with metastatic GIST have been sparse. One
study showed the high prevalence of severe fatigue among
GIST patients receiving tyrosine kinase inhibitor (TKI)
therapy when compared with healthy controls and reported
it to be associated with both a lower health-related quality of
life (HRQoL) and impairment in relation to all the func-
tional domains [10]. Another study described how the use of
TKI therapy to treat GIST resulted in an extended lifespan
and, further, how the patients enjoyed a good global quality
of life, although the vast majority of them reported expe-
riencing considerable fear of cancer progression, which
resulted in significantly higher levels of psychological dis-
tress, functional impairments, and difficulty making plans
for the future [11]. A qualitative study reported that patients
with metastatic GIST experienced five stages of disease
management, namely, crisis, hope, adaptation, “new nor-
mal,” and uncertainty [12]. Moreover, the ongoing uncer-
tainty as to whether the disease might become resistant to
treatment had a significantly negative impact on the par-
ticipants’ HRQoL [12]. Furthermore, GIST treatment could
affect the HRQoL. Imatinib and other TKIs are considered
moderately to well tolerated, and several of the adverse
effects can be ameliorated with supportive measures or
dosing modification [13]. While severe adverse effects are
infrequent, virtually all treated patients have side effects, the
most frequent being anemia, periorbital edema and watery
eyes, diarrhea, muscle cramps (typically in hands and legs),
fatigue, and nausea [13]. Compliance, i.e., adherence to self-
administered imatinib, can be a challenge for patients on
chronic therapy. In the SSGXVIII/AIO trial, the proportion
of patients who discontinued imatinib during the assigned
treatment period not due to disease recurrence was 26% in
the 36-month group compared to 13% in the 12-month
group [14]. +ere has also been observed a gap between the
medical perspective on how TKI therapy affects GIST pa-
tients and individual experiences of the side effects associ-
ated with the medication, with more than 50% of patients
describing partially debilitating effects that have a detri-
mental impact on their lives [15]. To the best of our
knowledge, no qualitative studies have performed an in-
depth investigation of how living with metastatic GIST af-
fects the family life, vocational life, social life, and leisure
time of patients in long-term clinical remission.
Living with metastatic cancer for years can, in many
ways, be seen as comparable to living with a serious chronic
illness, albeit one with an even more uncertain outcome. For
decades, sociologists and other researchers have discussed
chronic illness using terms such as “rupture”, “change,” and
“continuity”. Concepts such as “biographical disruption”,
[16], “loss of self” [17], and “illness as unhomelike being-in-
the-world” [18] have been developed to explore how pa-
tients’ self-understanding and identity are affected by
chronic or long-term illness. Cancer represents a serious
interruption in an individual’s life. People who develop
cancer generally construct it as a biographically disruptive
event with ongoing physical and psychosocial impacts [19].
When it lasts for a long time, cancer can change the lives of
those affected, as well as the lives of their families, pro-
foundly. Many cancer patients have to reorient themselves
and attempt to develop a new identity that corresponds to
their new circumstances [18].
+e aim of the present study was to explore how patients
with metastatic GIST experienced the psychosocial chal-
lenges associated with their disease and its treatment, as well
as how that experience influenced their practical, relational,
vocational, and existential life.
2. Methods
+is study has a qualitative and explorative design and
utilised a phenomenological and hermeneutical approach.
When it comes to qualitative research, phenomenology is a
concept that points to an interest in understanding phe-
nomena from the actors’ own perspectives and describing
the world as it is experienced by the informants, based on the
understanding that the reality is what people perceive [20].
+e hermeneutic approach is based on the fundamental idea
that all forms of human awareness are interpretative.+us, it
allows for the examination of the participants’ experiences in
light of the psychosocial perspective on health and illness
[18, 20]. In the current study, we sought to explore the
experiences of individual patients in their specific contexts.
Such research has a strong focus on reflective interpretation,
as made especially evident by Heidegger, who asserted that
description is inextricably linked to interpretation [21].
Comprehension is based on both the participant’s and the
researcher’s preunderstandings, as well as on the context,
and it develops throughout the entire research process [22].
+is article is an independent part of a larger study on
the treatment-related side effects of GISTfrom the individual
patient’s perspective [15].
2.1. Patients. Patients with metastatic GIST were identified
from the prospective sarcoma registry of the Department of
Oncology, Norwegian Radium Hospital, Oslo University
Hospital (NRH OUH). All the patients were undergoing
regular follow-up at the sarcoma outpatient clinics of the
NRH OUH. +e inclusion criteria for this study have pre-
viously been described [15]. Briefly put, all the patients had a
confirmed diagnosis of metastatic GIST, had been receiving
TKI therapy (imatinib or sunitinib) for at least two years
prior to their inclusion in the study, and had a stable disease.
A total of 20 patients were approached regarding their
possible participation in the study, and they all agreed to take
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part. Eleven women and nine men were included in the
study. +ey had a mean age of 61 years (range 36–85 years;
Table 1). In the results section, the participants are identified
according to their sex and age, woman (48).
2.2. Procedure. +e participants were recruited by their
treating oncologists at the NRH OUH.+ey received a letter
providing detailed information about all the relevant aspects
of the study. +ey were informed that participation would
not affect their treatment and were free to withdraw from the
study at any point.
+e first author conducted the interviews during a
scheduled routine clinical follow-up appointment at the
NRH OUH (n� 16) or at the individual participant’s home
(n� 4). +e interviews lasted for an average of 45 minutes.
+e semistructured interviews were conducted on a face-to-
face basis and then transcribed verbatim by a medical
secretary. +e participants were invited to narrate their
whole story from the point of diagnosis to the present day.
+eir experiences concerning their life situation as a cancer
patient with metastases controlled by effective medical
treatment were explored by questions such as the following:
what can you tell me about living with metastatic GIST?
What are the physical and practical consequences of the
disease and its treatment in everyday life? How does it affect
your family life, social life, working life, leisure life, and
existential life? +e participants commented that they ap-
preciated the opportunity to share their cancer story and,
further, that it was important for them to contribute to
research that might improve health-care services. All the
gathered information was stored confidentially, while the
transcripts were deidentified.
+e data protection officer at the NRH OUH approved
the study (approval number 2016/15358), and written in-
formed consent to participate was obtained from all the
patients.
2.3. Data Analysis. We used a thematic analysis [23] to
identify patterns of meaning across the dataset so as to
answer the research questions being addressed. +e patterns
were identified through a rigorous process of data famil-
iarisation, data coding, theme development, and revision. In
the present study, the entire dataset was thoroughly coded in
detail (inclusive and extensive) by hand by the first author
and partly by the last author. +en, the codes were divided
into categories, themes, and concepts [23]. +roughout the
whole process of analysis, the researchers regularly returned
to the original data to check the themes and quotes, as well as
to ensure that the meaning had not been lost during either
interpretation or translation [22].
3. Results
Living with metastatic GIST in long-term clinical remission,
in addition to the side effects of the required medication, led
to changes and limitations in the participants’ daily life.
Many of them expressed how tiredness, including impaired
memory, and physical challenges were among the
complaints that had a detrimental impact on their life. For
approximately half of the participants, uncertainty and fear
of disease progression were experienced as challenging.
Many participants had to make adjustments to ensure
that they had sufficient energy to cope with everyday life.
Furthermore, their regular activities in relation to their
family life, work life, social life, and leisure time had to be
adapted to the various challenges posed by the disease and its
treatment. Half of the participants stated that uncertainty
concerning drug resistance and the possibility of early death
were severely challenging and, further, that they had to work
hard to keep negative mental health issues at bay. Moreover,
they all considered the time spent waiting for their scheduled
follow-up computed tomography (CT) scan to be burden-
some (see Table 2).
3.1. Family Life-Normalisation and Adaptation.
Normalisation proved to be an ambiguous experience for all
the participants. It represented stability, which also implied
that certain problems had become part of their new normal.
+e majority reported that their family had become used to
the disease and that they now generally lived like a typical
family. Most participants considered family support to be
important and necessary. Several were keen to point out that
the disease had not destroyed their marriage, although they
Table 1: Demographic and clinical information of the participants.
Total number of patients 20











Time since primary diagnosis (years)∗ 8 (2–22)
Time receiving systemic treatment (years)∗ 6 (2–15)
Primary tumour localisation
Stomach 12 (60)









Number of abdominal surgeries (including surgery to the primary
tumour)




Values in parentheses are percentages unless otherwise indicated. ∗Values
represent the mean (range).
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had to admit that it had affected their life with their partner
in various ways. One man (56) who struggled with tiredness
and exhaustion noted, “I’m a bit sad really because I worry
that I might be setting some limits. I wish I had a bit more
energy and could give more to our relationship.” Several
participants struggled with a lack of desire or an inability to
engage in sexual activity. One of the men (52) who was
taking sunitinib said, “My sexual functioning has obviously
been affected by it, and I need medication to make things
work the way we want.” A lack of libido made it difficult to
meet expectations regarding intimacy in a romantic rela-
tionship. It also affected their identity as well as how they
perceived themselves. One woman (50) said that she had felt
less normal and less attractive since she stopped feeling like
regularly having sex with her partner. Another woman (51),
who no longer felt like having sex at all, stressed, “I’m glad I
live alone.”
Adaptation implied that the participants had adapted
their doings and tasks according to their new normal. +ose
who had children who were still living at home emphasised
that concerns related to their children were the most
worrying. +ey were afraid to die and so to leave their
children behind, and they were also worried about how this
would affect the children. One woman (53) commented that
she kept the seriousness of the disease hidden for her
children. +ey did not know that she had cancer. She
constructed two mental rooms, a grief room to which the
children were never admitted and a joy room into which she
invited the children and banished illness-related and exis-
tential thoughts.
“I entered the grief room when my boys were at school
because it’s very important to cry and chat [...] But once I
saw the boys come through the door, I put on my smile [...]
and went into the joy room. +ere I could be a mother [....]
and be normal.”
Several participants were grandparents. +ey reported
that their tiredness left them with little energy for their
grandchildren. As one grandfather (56) emphasised, “Being
with them should be a positive thing, but it really takes it out
of you. [....] I function like a second-rate cell phone. When it
has just been charged, it’s fine for a short time, but then the
batteries run down. And when they’re empty, well, that’s it.”
He pointed out that this was how he had felt in relation
to many areas of life since he became ill.
+e participants found it difficult to acknowledge that
their family members had to adapt to the restrictions caused
by their disease. At the same time, many of them emphasised
that the most important thing was to strive to achieve a life
that was as normal as possible.
3.2. Vocational Life Is Important but Requires Adjustment.
After being diagnosed with GIST, most participants wished
to continue to work in the same way as they had done before
cancer struck. +ey continued working either full or part
time after recovering from surgery. Despite the side effects of
the TKI therapy and the functional challenges that they
faced, the participants chose to work because the workplace
represented an important social arena to them. +ey wanted
to maintain their professional role and to contribute to
society.
Having a work-related identity was important tomany of
the participants. One woman (41) expressed how remaining
in employment was vital to her despite her demanding
cancer treatment. “As long as I canmanage it, I really want to
work. Being able to receive disability benefits is not an option
for me.” She had needed, however, to re-educate herself and
to change jobs, exercise regularly, cut down on her social life,
and go to bed early every night. Several other participants
confirmed that adjustments were necessary if they were to
cope with their job. For some, it took them a long time to get
started in the morning due to the side effects of their
medication. Stress related to regularly taking their medicine
caused discomfort, and several participants had adapted to
certain eating routines related to the intake of medicine in an
effort to avoid nausea. +is, in conjunction with their
tiredness, caused some participants to avoid starting work
early or scheduling activities during the morning. Addi-
tionally, edema proved to be a challenge. One woman (52)
commented, “Of course, having a lot of water made life
difficult. [. . .]. I had to get up at half past four in the morning
to be at work for seven. [...] I needed to urinate about two
litres every morning.” Another woman (51) expressed how
she faced major challenges concerning her concentration
Table 2: +emes extracted from the participants interview.
+emes Family life-normalisationand adaptation
Vocational life is important but
requires adjustment
Limitations to social life
and leisure time













A normal life as possible
Wish to work
Adjustments necessary




Adapted to routines in the
morning
Concentration problems
Stop working was difficult but a
relief
Little energy for social and
physical activities
Avoid social activities or
make adjustments
Reduced physical activities




Difficult to explain the
limitation to others
Toilet access problem
Uncertainty due to drug resistance
and fear of premature death
Relaxed to living with metastatic
cancer
More afraid of losing ability to
function
Limbo between uncertainty and
hope
Follow-up was burdensome for all
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and memory, which also had an impact when she was at
work. “I often ask myself if I am developing dementia.” She
worked part time but aimed to return to full-time work in
the future. Several participants said that it was both desirable
and possible to work if adjustments were made and working
hours were reduced.
Some participants had managed to keep working for
several months or a few years, while others had continued to
work for a very long time after being diagnosed with GIST.
However, due to side effects such as tiredness, cognitive
challenges, pain, and nausea, it was not feasible for all of
them to continue to work for as long as they wanted. +ose
who had given in, retired, or claimed disability benefits
believed it was a pity that they had had to leave their job,
although they also considered it to have been necessary.
While choosing to stop work was difficult, several partici-
pants stressed that they felt relief when they had finally made
the decision. One woman (50) expressed, “+e only thing I
did was go to work. [...]. It was like my whole identity. [. . .]
But then it dawned on me that I could not live like that. I
could not just go to work and then come home and sleep
until I went to work again.” She had applied for disability
benefits and described the feeling of being eligible as, “An
unbelievable relief. Now I can just concentrate onmyself and
my family.”
3.3. Limitations to Social Life and Leisure Time. Most par-
ticipants reported having a less active social life after being
diagnosed with metastatic GIST and starting imatinib.
Having little energy and so feeling the need to go to bed early
and to rest a lot, as well as having low alcohol tolerance and
requiring dietary adjustments, made many participants ei-
ther avoid social activities altogether or adapt to enable them
to socialise.
Several participants reported having little surplus energy
for socialising and so often having to make adjustments. One
man (56) commented, “Like, when I’m invited to a 50th an-
niversary party, [...] I have to prepare for it properly. Both
mentally and physically, for the extra challenges, I’ll be facing at
the weekend”. He felt that it was sad and a shame that he had
had to “put the brakes on” his sociable and sporty wife’s life,
although they had adjusted well. “We try to find solutions. To
find strategies all the time so that we can do the things we like,
that we think are meaningful.” Many participants emphasised
how socialising wore them out, meaning that they had to rest
for one or more days afterwards.
+e disease also affected the participants’ leisure time
and, in particular, their physical activity. Many of them had
to reduce their level of participation, stop certain activities
altogether and/or change hobbies. +ey had to apportion
their energy, which meant that skiing and walking trips
became lower key, shorter, took longer, or were no longer
feasible. +ey pointed out that it was difficult for other
people to understand how they needed to take steps to
ensure they had enough energy to be sociable and active.
Despite their limited energy, many participants emphasised
how exercise and outdoor activities were important in terms
of keeping fit and decreasing both tiredness and exhaustion.
As one woman (74) commented,
“Fatigue, yes, I’ve experienced it. However, after I started
exercising quite a bit, it actually disappeared. It helps a lot.
But obviously there are many days when I feel drained, as I
call it. +en I just sit down and watch TV.”
Another woman (53) reported needing constant access
to a toilet, which hampered her ability to engage in social
activities. She could no longer join others on trips to the
mountains or the seaside. “I have to run to the toilet. +at’s a
bit of a barrier when you’re out with other people and there’s
no possibility to do that. [..] So you dread it”. Some par-
ticipants stressed that it was difficult to explain to others the
limitations and adjustments they needed to function now.
+ey felt that it was easier to avoid socialising.
3.4. Keeping Negative Mental Health Issues at Bay. +e
participants’ mental health was an explicit issue, albeit not in
clinical terms such as anxiety or depression. On the contrary,
their coping issues were related to existential concerns,
fundamental uncertainties, and fear.+e participants related
a number of existential challenges, an uncertainty due to
drug resistance and a fear of premature death in various
ways. Fear was perceived as a demanding companion that
caused stress to more than half of the participants. +ey
emphasised just how taxing it was to live with dormant
metastases in their body. One woman (68) reflected on the
sinister and nagging feeling that everything could change.
“+e most difficult thing is keeping negative thoughts at
bay. And not getting stuck thinking about the worst-case
scenario, as I did last summer when I got the disappointing
news about developing metastasis.”
Another female participant (50) said, “+e thought of
drug resistance is the same as thinking about death.” A man
(52) who had lived with metastatic GIST for a long time
commented that thoughts about death brought gravity into
everyday life. He reported having thought a lot about death
and even having planned his own funeral. He considered the
uncertainty to be the worst part.
“Without my psychiatrist, psychologist, doctor, and
some very good friends, my life would have gone to hell. I
think I’d have committed suicide. Because it’s a death
sentence and the doctors still only have limited knowledge
about it. +ey can only provide me with limited answers.”
He emphasised that despite having lived for more than
two decades with metastatic GIST, there were still no so-
lution to his problem available from his doctors who con-
tinued saying “We believe, we hope, we are counting on.”
One woman (41) commented that she always had some
short-term and affordable goals in mind to help her to
manage the unpredictable. “My first goal was to stay alive
until my children started kindergarten, the next was when
they started school, then high school and confirmation.” In
this way, she managed to look to the future in a step-wise
manner and so keep hope alive. Several participants talked
about the distinction between being afraid of death and
fearing that they would lose their life. +ey were not nec-
essarily afraid of dying, but rather they were anxious about
dying early and so losing a good life and everything that
matters to them. +ey felt that they still had much to do in
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life. Additionally, for some participants, losing the ability to
function scared them more than the fear of death.
Nearly half the participants gave the impression of being
relaxed with regard to living with metastatic cancer. +ey
experienced little fear concerning drug resistance and had
not thought much about death. As one man (73) com-
mented, “I’ll cross that bridge when I come to it.” Another
man (67) stated, “I have never thought that I’ll die of it.”
Some participants were aware that they were now facing a
time limit and accepted that they were not going to live as
long as they had expected. One woman (53) acknowledged
that “No, I do not really think so much about it in everyday
life. I think I’ll just take it as it comes. You do not expect to
live for as long as you would have done otherwise. [...]. I fully
understand that. [...] I cannot do anything about it, so I do
not let it bother my mind because I’m doing my best to live
in the here and now.”
+e participants related stories about living in a kind of
limbo between uncertainty and hope. For most of them, this
feeling became particularly apparent during scheduled time
of follow-up. While in everyday life, in the time between
scheduled follow-up visits, many of the participants did not
think much about cancer, drug resistance problems, or
death, such thoughts and feelings always surfaced when they
were due to attend an appointment. Some participants
claimed that they felt a sense of discomfort in their stomach
and became more sensitive to pain. Many reported feeling
bad, having intrusive thoughts and experiencing diverse
emotions, which are all recognised as symptoms of internal
stress. One woman (68) stated, “I get very anxious before
each CT, before I receive the report. My next control is in
March, but before that it’s just like I’m free, you know, a
period in which I can somehow relax, before I begin to dread
the next CT.”
4. Discussion
+e participants described how living with metastatic GIST
and its treatment posed challenges in relation to everyday
life. +ey emphasised how this affected many facets of daily
life, including family life, vocational life, and social life. In
addition, living with uncertainty and an unsettled future
proved burdensome for the participants.
+e ways in which they managed family life, in relation
to both their spouse and their children, were important
components of the new normal. Several participants
expressed how a lack of energy and, for some, impaired
sexuality affected life with their partner and what they could
do together as a couple. Prior studies have indicated that for
both men and women, cancer has a significant impact on the
everyday life of their spouse [24, 25]. Spouses tend to
struggle to achieve a balance between focusing on their own
needs and meeting the needs of their partners as they un-
dergo treatment for metastatic cancer. For some, their role
seems to shift from being a spouse to being part of a larger
support team, which causes their own life to be neglected
[24]. A qualitative study investigating the relational life of
advanced prostate cancer patients indicated that the side
effects of hormone therapy may impact their spouses’ daily,
sexual and leisure activities, their emotional closeness, and
the sincerity and patterns of communication between them
[25]. Although the participants in this study recognised their
own inadequacies in terms of cohabitation, they felt that the
best way to cope with the situation was to adjust everyday life
so that both partners could meet each other’s needs. +is
might be an important finding, as research has indicated that
less cancer-related distress is experienced by couples who
work together to manage shared stress and who adopt a “we”
approach [26]. Fatigue posed a considerable challenge for
many of our participants, which is in accordance with the
findings of another study conducted among GIST patients
[10]. Fatigue affected our participants’ family life and left
them unable to contribute as much as they wanted in re-
lation to their spouse, children, and grandchildren. +ere is
now growing recognition of the complexity of fatigue, which
shows significant interindividual variability in terms of its
severity and expression, as well as a multifactorial etiology
[27]. Studies have indicated that continuing health-care and
follow-up clinics do not focus sufficiently on the late effects
of cancer, including fatigue and cognitive ailments [15, 28].
For those participants who had children, fear of the
future and the potential that death might take them away
from their children were the most demanding aspects of
living with metastatic GIST. Research has shown that par-
ents with cancer tend to face the challenges associated with
illness by making the best of it, putting the needs of their
children first and trying to maintain a normal family life
[29]. +us, the provision of sufficient support for parents
with cancer is of vital importance. Relevant parenting issues
should be acknowledged by health-care providers as an
important facet of care and as a key mechanism for reducing
parental stress and the psychological distress experienced by
the whole family [30].
+e desire to maintain daily routines and a sense of
normality was a prominent concern for all our partici-
pants. Despite being metastatic GIST patients, it was
important for them to consider themselves healthy and,
thus, not to be characterised as a cancer patient [15].
Chronic cancer patients wish to be physically active and
socially engaged, but cyclical symptoms and side effects
prove challenging in this regard [31]. Cancer patients may
engage in a process of mobilising their resources to
“normalize in the face of disruption” [16]. Normalisation
has been identified as a common coping strategy among
individuals living with multiple conditions, including
cancer [32]. One of the six distinct normality typologies
proposed by Sanderson et al. [32] is “struggling for
normality, presenting a normal life whatever the cost”.
Such an approach was essential for one of the mothers in
our study due to her desire to protect her children. Several
participants emphasised how striving for normalisation
entailed adjustments, although it was of great importance
to their family life.
+e majority of our participants worked full time or part
time after being diagnosed with metastatic GIST. +is was
the case even though Norway is a compassionate society that
will ensure you survive financially even if you are unable to
work. Having a work-related identity was important to the
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participants, while going to work was associated with having
a normal and social life. +ey chose to work, although
adjustments were required for them to be able to do so.
Being excluded from the world of employment due to cancer
can affect people’s everyday structure and could also result in
a reduced social life, which both give life richness and
meaning [33]. A quantitative study of 668 patients in
working-age with metastatic cancer showed that 35%
worked full or part time, whereas 45% did not work because
of illness. Overall, 58% reported some change in employ-
ment due to illness [34]. In general, due to defining people’s
social status and personal identity, employment is an im-
portant factor in relation to social integration [35]. +is
indicates that health-care providers should support those
with metastatic cancer/GIST in remission to continue
working rather than being declared sick or disabled earlier
than necessary.
Many of our participants reported struggling with a lack
of energy, eating restrictions, and the need for constant
access to a toilet. Some participants stated that they were
now excluded from sport and outdoor activities, as well as
from social gatherings, when compared with their life before
cancer struck. Research indicates that physical activity has a
positive effect on cancer survivors’ well-being and general
health [36, 37]. A meta-analysis of randomised controlled
trials indicated that physical activity reduces fatigue and
improves QoL among cancer survivors [38]. Our partici-
pants emphasised that both outdoor life and physical ac-
tivities were important to them and, further, that exercise did
them good. However, the inability to keep up with healthy
peoples’ activity levels due to fatigue, eating restrictions, and
toilet needs led to them participating in fewer social activities
and experiencing exclusion from arenas that were important
to them.
Only a few studies have addressed the fear of progression
and uncertainty in patients with metastatic GIST [11, 12, 39].
GIST patients with a high level of fear experience signifi-
cantly more general and cancer-specific distress than pa-
tients who report less fear [11]. Moderate-to-high levels of
fear of cancer recurrence affect approximately half of all
cancer survivors and up to 70% of those in vulnerable
groups, and managing fear is one of the most common
unmet needs among cancer survivors [40]. However, half of
our participants did not think much about recurrence or
death in their daily life. Yet, concerns related to their
disease becoming resistant to TKI therapy became more
evident during the follow-up period. +is time period
proved to be stressful for all of them. Acknowledging this
stress could serve to improve physician-patient commu-
nication. Greater knowledge concerning the fear of re-
currence may help to identify patients who might benefit
from evidence-based psychological treatment [39]. For
example, an app-based stress management tool has been
shown to provide much appreciated support to cancer
survivors [41]. A pilot project indicated that the 25 par-
ticipants who tested the app reported a significant decrease
in their perceived stress and anxiety, as well as a decrease in
their fatigue [42]. For metastatic GIST patients in a stable
phase who are being treated with TKI inhibitors, such an
app-based tool might be of interest if psychosocial face-to-
face intervention is not feasible. In addition, two studies in
chronic myeloid leukemia patients on TKIs showed that
cognitive behavioural therapy improved qualitative level of
functioning and coping with treatment-related fatigue
[43, 44]. +e translational value for GIST patients warrants
further studies.
To the best of our knowledge, no validated question-
naire/tools to measure QoL or HRQoL are available spe-
cifically for GIST patients. Nevertheless, one study in GIST
explored the psychosocial impact by using +e Psychosocial
Assessment Tool (PAT2.0) [45, 46]. Furthermore, +e
EORTCQuality of Life Questionnaire Core 30 [47] was used
by Custers et al. [11] and Yoo et al. [48] to study HRQoL and
psychosocial consequences of treatment in GIST.
Our findings indicate that a holistic view of health is
crucial for those who are living in limbo between having
metastatic cancer and receiving effective treatment. Health
professionals’ recognition of the psychosocial challenges
faced by metastatic GIST patients during follow-up might
present an opportunity for dialogue that could provide them
with the necessary assistance in terms of health-care, as well
as understanding and knowledge of how they can cope with
and prepare for a better life. A simple approach to this might
be to educate the GIST patients about fatigue, cognitive
problems, sexuality, pain, physical activity, work, and social
life.
+e relatively small sample size and the fact that the
participants were recruited from just one institution may
limit the generalisability of this study. Nevertheless, the use
of a strategic selection procedure in this study provided
robust results regarding this particular group of patients
with metastatic GIST. In qualitative research, we do not seek
to gather representative data, but rather to illuminate the
phenomena that the participants experience from their own
perspectives. +e selection proved to be adequate in this
study, as the narratives were rich and full of nuanced
examples.
5. Conclusions
For the participants in this study, it was important to strive
to live as normal a life as possible despite the challenges they
faced due to their disease and its treatment. +us, they
adapted their lives to these limitations. Family life,
remaining in employment, maintaining a social life, and
being active, not to mention dealing with various existential
challenges, were all of great concern.
New medical treatments that prolong survival and in-
duce long-term clinical remission are now available for
several forms of metastatic cancer. Hence, other groups of
patients may have similar information needs to those we
have described in relation to GISTpatients. Further research
into how daily practical and psychosocial life is affected in
patients with chronic cancer, including metastatic GIST, as
well as prospectively studied interventions, is warranted.
+is might provide health-care providers with clues as to
how best guide and support patients through their emotional
journey and so improve their QoL.
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